

TR-1: Standard form for notification of major holdings

**1. Issuer Details**

**ISIN**

GB00BDGKMY29

**Issuer Name**

BIOPHARMA CREDIT PLC

**UK or Non-UK Issuer**

UK

**2. Reason for Notification**

An event changing the breakdown of voting rights

**3. Details of person subject to the notification obligation**

**Name**

Adage Capital Management L.P.

**City of registered office (if applicable)**

**Country of registered office (if applicable)**

US

**4. Details of the shareholder**

Name	City of registered office	Country of registered office
Adage Capital Partners, L.P.		

**5. Date on which the threshold was crossed or reached**

29-Sep-2022

**6. Date on which Issuer notified**

19-Nov-2024

**7. Total positions of person(s) subject to the notification obligation**

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	12.000000	0.000000	12.000000	164014169
Position of previous notification (if applicable)				

**8. Notified details of the resulting situation on the date on which the threshold was crossed or reached**

**8A. Voting rights attached to shares**

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB00BDGKMY29	0	164014169	0.000000	12.000000
Sub Total 8.A	164014169		12.000000%	

**8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))**

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1				

**8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))**

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights

Sub Total 8.B2					

#### 9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Adage Capital Management, LP	Adage Capital Partners GP, L.L.C. (as general partner of Adage Capital Partners, L.P.)	12.000000		12.000000%

#### 10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

#### 11. Additional Information

Our filing is late because we misunderstood how the incremental reporting thresholds apply to Biopharma Credit PLC under DTR 5. We have now taken legal advice and implemented procedures to monitor and report our positions in accordance with our obligations under DTR 5.

#### 12. Date of Completion

19-Nov-2024

#### 13. Place Of Completion

London, England

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

HOLURORRSVUAUAA